Darbepoetin alfa - Kirin/Amgen

Drug Profile

Darbepoetin alfa - Kirin/Amgen

Alternative Names: Aranesp; Darbepoetin-α; KRN-321; Nesp; Nespo; Novel erythropoiesis stimulating protein

Latest Information Update: 13 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kirin-Amgen
  • Developer Amgen; Kirin-Amgen; Kyowa Hakko Kirin
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaemia
  • Phase III Breast cancer

Most Recent Events

  • 19 Oct 2017 Amgen completes the START-CKD trial in Anaemia in Puerto Rico and USA (SC) (NCT01652872)
  • 05 Oct 2017 Amgen completes a phase II trial in Anaemia (Chemotherapy-induced, In adolescents, In children, In infants, In neonates) in Belgium (IV, Injection) before October 2017 (EudraCT2008-001721-34)
  • 14 Sep 2017 Amgen completes the phase III ARCADE trial in Anaemia (in patients with myelodysplastic syndromes) in Austria, Belgium, Czech Republic, France, Germany, Greece, Italy, Spain and Switzerland (NCT01362140)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top